Engitix-GSK Collaboration Targets Liver Fibrosis Regression via ECM Platform
The deal signals pharma's growing interest in fibrosis biology that increasingly intersects with hepatoprotective nutra…
The deal signals pharma's growing interest in fibrosis biology that increasingly intersects with hepatoprotective nutra…
The Austin-based biotech's lead candidate targets the DR3 pathway — a mechanism drawing growing interest in immune-medi…
The amendment signals regulatory confidence in next-generation cell therapy manufacturing as solid-tumor CAR-T programs…
The move signals growing operator interest in CPG adjacency as restaurant brands leverage existing consumer loyalty to …
The gut-health biologics pipeline inches forward as a vedolizumab biosimilar clears a key regulatory milestone — with i…
The gut-targeted integrin inhibitor category draws biosimilar competition as regulators advance interchangeability revi…
The BLA acceptance marks a regulatory milestone for the gut-inflammation biologics pipeline, with biosimilar competitio…
As bioactive ingredient validation demands tighten, contract development organizations with end-to-end analytical infra…
The CDMO's integrated testing infrastructure targets a critical bottleneck in biologics development: closing the gap be…
The Dutch CDMO signals growing demand for end-to-end analytical support as biotech sponsors accelerate vaccine and biol…
As Asia-Pacific milk tea culture collides with functional formulation trends, regional brands are staking out different…
Hepatocyte-directed vesicle technology positions the delivery platform at the intersection of pharma and advanced nutra…